BioSpace News Archive

Innovative LDL-C Lowering Treatment has now Been Approved for High-Risk Patients in China With Cardiovascular Disease

LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that the Company has formed a scientific advisory board (SAB) to assist the Company in product positioning and its go-to-market strategy

Having long been a trust-worthy supplier for chemicals widely applied in drug discovery, chemistry and life science, BOC Sciences’ management recently decides to take another step forward and broaden its business range.

Polycystic ovary disorder (PCOS) is a usual hormonal endocrine issue that influences women of baby bearing age that is 15 to 49 years

RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AxoGen, Inc.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal 2019 first quarter ended December 31, 2018.

The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on January 24, 2019.

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today provides a business and unaudited trading update for the year ended 31 December 2018.

PharmaMar (PHM:MSE) announces that the Committee for Orphan Medicinal Products (COMP), from the EMA, has given its positive opinion for the approval of Orphan Drug status to Zepsyre® (lurbinectedin) for the treatment of small-cell lung cancer.

MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces that the Food and Drug Administration (FDA) and Health Canada have cleared Investigational New Drug applications (IND/CTA) for its lead candidate MGB-BP-3